Adaptimmune Therapeutics PLC – (ADAP) Sees Significant Drop in Short Interest

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 1,074,906 shares, a decline of 32.5% from the January 12th total of 1,592,956 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average trading volume of 851,458 shares, the short-interest ratio is presently 1.3 days.

Several equities analysts have weighed in on ADAP shares. TheStreet raised Adaptimmune Therapeutics from a “d” rating to a “c” rating in a report on Thursday, November 2nd. Zacks Investment Research cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. SunTrust Banks reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Adaptimmune Therapeutics in a report on Friday, November 10th. ValuEngine cut Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub cut Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $11.58.

Adaptimmune Therapeutics (NASDAQ ADAP) opened at $7.94 on Monday. Adaptimmune Therapeutics has a 52 week low of $3.88 and a 52 week high of $9.70. The stock has a market capitalization of $743.87, a price-to-earnings ratio of -10.45 and a beta of 1.74.

Several institutional investors and hedge funds have recently modified their holdings of the company. Baillie Gifford & Co. increased its stake in shares of Adaptimmune Therapeutics by 4.2% in the 3rd quarter. Baillie Gifford & Co. now owns 1,379,304 shares of the biotechnology company’s stock valued at $11,297,000 after purchasing an additional 55,996 shares during the last quarter. BlackRock Inc. increased its stake in shares of Adaptimmune Therapeutics by 43,632.6% in the 4th quarter. BlackRock Inc. now owns 787,187 shares of the biotechnology company’s stock valued at $5,258,000 after purchasing an additional 785,387 shares during the last quarter. Artal Group S.A. increased its stake in shares of Adaptimmune Therapeutics by 40.0% in the 4th quarter. Artal Group S.A. now owns 700,000 shares of the biotechnology company’s stock valued at $4,676,000 after purchasing an additional 200,000 shares during the last quarter. Graticule Asia Macro Advisors LLC bought a new position in shares of Adaptimmune Therapeutics in the 3rd quarter valued at $3,242,000. Finally, Rathbone Brothers plc increased its stake in shares of Adaptimmune Therapeutics by 60.1% in the 3rd quarter. Rathbone Brothers plc now owns 321,050 shares of the biotechnology company’s stock valued at $2,629,000 after purchasing an additional 120,525 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Adaptimmune Therapeutics PLC – (ADAP) Sees Significant Drop in Short Interest” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/12/adaptimmune-therapeutics-plc-adap-sees-significant-drop-in-short-interest.html.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply